Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Rhea-AI Summary

Palisade Bio (NASDAQ: PALI) announced the acceptance of its abstract for poster presentation at the 2025 Crohn's & Colitis Congress in San Francisco. The presentation, scheduled for February 7, 2025, will showcase research on PALI-2108, a colon-specific PDE4B inhibitor prodrug. The poster, titled 'PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model,' will be presented during the Poster and Exhibition Hall Reception at Moscone West.

Positive

• Acceptance of research for presentation at a major industry congress indicates scientific validation of PALI-2108 development
• Preclinical data shows PALI-2108 reduces ulcerative colitis symptoms in mouse model

Negative

• None.

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.

Details of the poster presentation are as follows:

Session: Poster and Exhibition Hall Reception
Poster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model
Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PST
Presentation Location: Level 1 – Exhibition Hall – Moscone West

For more information about the congress, please visit crohnscolitiscongress.org.

About Palisade Bio 

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

FAQ

What is PALI-2108 and how does it work in treating ulcerative colitis?

PALI-2108 is a colon-specific PDE4B inhibitor prodrug that is activated in the colon and has shown effectiveness in reducing ulcerative colitis symptoms in preclinical mouse models.

When and where will Palisade Bio present their PALI-2108 research at the 2025 Crohn's & Colitis Congress?

Palisade Bio will present their PALI-2108 research on February 7, 2025, from 5:00 PM to 6:30 PM PST at the Exhibition Hall, Level 1 of Moscone West in San Francisco.

What are the key findings from Palisade Bio's PALI-2108 preclinical studies?

The preclinical studies demonstrated that PALI-2108 is activated in the colon and effectively reduces ulcerative colitis symptoms in an acute colitis DSS mouse model.

How might the presentation at the 2025 Crohn's & Colitis Congress impact PALI stock?

The presentation represents scientific validation of PALI-2108's development and could increase visibility within the medical community, potentially impacting investor interest in PALI stock.